REG-Mydecine Innovations Group Inc: Total Voting Rights

Mydecine InnovationsAnnouncement

28/03/2024 07:15

 

 

MYDECINE INNOVATIONS GROUP INC.

(the "Company" or "Mydecine")

 

TOTAL VOTING RIGHTS

 

 

VANCOUVER, BC - (28 March 2024) In accordance with the FCA's Disclosure
Guidance and Transparency Rules, as at 28 March 2024, the Company's issued
share capital consists of 58,127,177 Ordinary Shares of no par value, each
with one voting right. The Company does not hold any Ordinary Shares in
treasury. Therefore, the total number of voting rights in the Company is
58,127,177.

The above figure of 58,127,177 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

 

For more information, please contact:

 

Media Contact

pr@mydecineinc.com

 

Investor Relations

investorrelations@mydecineinc.com

_____________________________

On behalf of the Board of Directors
Joshua Bartch, Chief Executive Officer contact@mydecineinc.com 
AQSE Corporate Advisor

Novum Securities Limited      

David Coffman/ George Duxberry

Tel: +44 (0)207 399 9400

 

For further information about Mydecine, please visit the Company's profile on
SEDAR at https://sedar.com/ or visit the Company's website at
https://www.mydecine.com/.

 

About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a biotechnology company developing the next
generation of innovative medications and therapies to address mental health
disorders such as nicotine addiction and post-traumatic stress disorder
(PTSD). The core strategy blends advanced technology with an elaborate
infrastructure for drug discovery and development. Mydecine's dedicated
multinational team constantly develops new paths for breakthrough treatment
solutions in areas with considerable unmet needs. By collaborating with some
of the world's leading specialists, the Company aspires to responsibly speed
up the development of breakthrough medications to provide patients with safer
and more effective treatment solutions. At the same time, Mydecine's approach
focuses on the next generation of psychedelic medicine by creating innovative
compounds with unmatched therapeutic potential through its clinical trial
efforts with world-class scientific and regulatory expertise.  
Learn more at: https://www.mydecine.com/ and follow the Company on Twitter,
LinkedIn, YouTube, and Instagram.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved